CN102784310A - Traditional Chinese medicine composition for treating headache and dizziness of apoplexy sequela - Google Patents
Traditional Chinese medicine composition for treating headache and dizziness of apoplexy sequela Download PDFInfo
- Publication number
- CN102784310A CN102784310A CN2012103044695A CN201210304469A CN102784310A CN 102784310 A CN102784310 A CN 102784310A CN 2012103044695 A CN2012103044695 A CN 2012103044695A CN 201210304469 A CN201210304469 A CN 201210304469A CN 102784310 A CN102784310 A CN 102784310A
- Authority
- CN
- China
- Prior art keywords
- parts
- headache
- chinese medicine
- dizzy
- apoplexy sequela
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 62
- 208000006011 Stroke Diseases 0.000 title claims abstract description 42
- 206010008190 Cerebrovascular accident Diseases 0.000 title claims abstract description 40
- 208000002173 dizziness Diseases 0.000 title claims abstract description 38
- 206010019233 Headaches Diseases 0.000 title claims abstract description 36
- 231100000869 headache Toxicity 0.000 title claims abstract description 36
- 239000000203 mixture Substances 0.000 title claims abstract description 23
- 241000271039 Agkistrodon Species 0.000 claims abstract description 17
- 241000717739 Boswellia sacra Species 0.000 claims abstract description 16
- 241001489978 Eupolyphaga Species 0.000 claims abstract description 16
- 241000522620 Scorpio Species 0.000 claims abstract description 16
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 13
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 13
- 241001057584 Myrrha Species 0.000 claims description 15
- 239000000835 fiber Substances 0.000 claims description 13
- 241000255791 Bombyx Species 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 9
- 239000006187 pill Substances 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 19
- 208000024891 symptom Diseases 0.000 abstract description 11
- 208000029078 coronary artery disease Diseases 0.000 abstract description 7
- 206010003210 Arteriosclerosis Diseases 0.000 abstract description 6
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract description 6
- 208000002193 Pain Diseases 0.000 abstract description 5
- 239000004863 Frankincense Substances 0.000 abstract description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 4
- 239000009490 scorpio Substances 0.000 abstract description 4
- 208000001132 Osteoporosis Diseases 0.000 abstract description 3
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 241000255789 Bombyx mori Species 0.000 abstract 1
- 240000007311 Commiphora myrrha Species 0.000 abstract 1
- 235000006965 Commiphora myrrha Nutrition 0.000 abstract 1
- 235000007265 Myrrhis odorata Nutrition 0.000 abstract 1
- 206010033425 Pain in extremity Diseases 0.000 abstract 1
- 241000270273 Ptyas dhumnades Species 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 239000012567 medical material Substances 0.000 description 9
- 238000005303 weighing Methods 0.000 description 8
- 230000017531 blood circulation Effects 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 206010019468 Hemiplegia Diseases 0.000 description 3
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 230000036770 blood supply Effects 0.000 description 3
- 208000036319 cervical spondylosis Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 208000037920 primary disease Diseases 0.000 description 3
- 208000005801 spondylosis Diseases 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 206010042772 syncope Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000003028 Stuttering Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000008561 buyang huanwu Substances 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 208000001286 intracranial vasospasm Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Abstract
The invention discloses a traditional Chinese medicine composition for treating headache and dizziness of apoplexy sequel, which is prepared from the following traditional Chinese medicines in parts by weight: 5-15 parts of eupolyphaga seu steleophaga, 5-25 parts of zaocys dhumnades, 5-25 parts of agkistrodon, 5-15 parts of scorpio, 5-25 parts of radix notoginseng, 10-30 parts of olibanum, 10-30 parts of prepared myrrh, 10-30 parts of rhizoma gastrodiae, 10-30 parts of silkworm larva and 15-45 parts of radix angelicae sinensis. The traditional Chinese medicine composition disclosed by the invention can be utilized to treat headache and dizziness of apoplexy sequel and have the effects that toxic and side effects are fewer, the effect is quick, and apoplexia can be prevented. The invention has the treatment effects to other cerebrovascular diseases, dizziness, headache, waist pain, leg pain, and the like, and is capable of relieving arteriosclerosis, hyperlipidemia and coronary disease and various symptoms caused by osteoporosis.
Description
Technical field
The present invention relates to a kind of dizzy Chinese medicine composition of apoplexy sequela headache of treating, belong to medical field.
Background technology
The sickness rate of apoplexy rises year by year in recent years.Apoplexy has another name called ACVD, and apoplexy is with hemiplegia, aphasia, even sudden loss of consciousness is clinical primary symptom, in case people's apoplexy, gently then facial hemiparalysis, stuttering, the hemiplegia of stiff tongue language; Heavy then sudden syncope, syncope, pupil loose wild, so claim the mankind " No. three killer ".The primary disease onset is more anxious, and brain infringement symptom peaks at short notice.The apoplexy sickness rate is high, and disability rate is high, and mortality rate is high.
In Chinese medicine, apoplexy has another name called apoplexy.Huangdi's Internal Classics was main with symptom to the existing many records of apoplexy at that time on concept, was described as " hemiplegia ", " sudden falling down " etc., then heavily acupuncture of treatment." golden plaque outline " beginning is named and is apoplexy to the Han dynasty.Qin Han thinks that until Tang of Sui the primary disease cause of disease is main with " apoplexy due to deficiency exogenous wind ", and treatment is many with wind dispelling, the square medicine set upright, and Prescriptions Worth Thousand Gold for Emergencies is also advocated with medicated wine and moxibustion therapy.Song, gold, unit period, to apoplexy because of having carried out comparatively deep discussion, non-wind theory rise, think primary disease to betide fire of moxibustion expectorant void relevant, not merely due to the exogenous wind.To the Ming Dynasty, endogenous wind is that the main cause of disease is said and obtained certainly, thereby promotes the reform of treatment, method of treatment that occur pleasantly reducing phlegm, invigorating the spleen and benefiting QI, nourshing blood and promoting blood circulation, replenishing kidney-YIN etc. is new and prescription accordingly, and start to close and take off treatment.The Qing Dynasty, the apoplexy specification area is meticulous, as in affection by exogenous wind, syndrome similar to wind disease, the moon, in the sun, heat-blockage, constipation due to cold pathogen etc.; Dialectical medication is more precise and appropriate, formulates multiple effective prescription, like the Wang Qingren BUYANG HUANWU TANG, still is widely used in clinical so far.
China is with a long history, and Chinese medicine is flourishing, has stayed the method and the prescription of many treatment apoplexy.But all be that clinical executing controlled, evolution is made up the prescription, and fries in shallow oil into decoction again and lets patient obey down, uses extremely inconvenient.
Summary of the invention
The technical problem that the present invention will solve provides a kind of dizzy Chinese medicine composition of apoplexy sequela headache of treating, and it is dizzy to can be used for treating the apoplexy sequela headache, and instant effect, toxic and side effects are little, and can prevention of stroke.The present invention is effective in cure to other cerebrovascular and dizziness, headache, waist, skelalgia etc., and the various symptoms that can alleviate arteriosclerosis, hyperlipidemia, coronary heart disease and caused by osteoporosis.
For solving the problems of the technologies described above, the technical scheme that the present invention taked is: a kind of dizzy Chinese medicine composition of apoplexy sequela headache of treating, form by following Chinese medicine by weight:
Eupolyphaga 5～15 Zaocyss 5～25
Agkistrodon 5～25 Scorpios 5～15
Radix Notoginseng 5～25 bright Olibanums 10～30
Myrrha (processed) 10～30 whole days fiber crops 10～30
Bombyx Batryticatus 10～30 Radix Angelicae Sinensis 15～45.
A kind of dizzy Chinese medicine composition of apoplexy sequela headache of treating, preferably form by following Chinese medicine by weight:
Eupolyphaga 10 Zaocyss 15
Agkistrodon 15 Scorpios 10
Radix Notoginseng 15 bright Olibanums 20
Myrrha (processed) 20 whole days fiber crops 20
Bombyx Batryticatus 20 Radix Angelicae Sinensis 30.
A kind of dizzy medicine of apoplexy sequela headache of treating is processed by above-mentioned Chinese medicine composition and pharmacy acceptable auxiliary.Adjuvant commonly used has the conventional adjuvant in this areas such as solvent, diluent, binding agent, cosolvent, suspending agent and stabilizing agent, for example dextrin, starch, yellow starch gum and Icing Sugar etc.
The dizzy medication preparation of preferred treatment apoplexy sequela headache becomes peroral dosage form.
Peroral dosage form is honeyed pill, condensed water honeyed pill, the watered pill, granule, capsule, tablet, powder, unguentum or oral liquid.
Preferred oral dosage form of the present invention is a capsule.
Medicine of the present invention is made up of eupolyphaga, Zaocys, Agkistrodon, Scorpio, bright Olibanum, Myrrha (processed), whole day fiber crops etc.The eupolyphaga acrid in the mouth is returned Liver Channel, removing blood stasis, reunion of fractured tendons and bones; Zaocys, Agkistrodon dispelling wind and removing obstruction in the collateral, pain relieving, this three flavors medicine is a principal agent, and liver-wind is put out, and blood stasis is lived, and it is logical to block, and plays the therapeutical effect to cerebrovascular.Cerebrovascular curative in the past is main with blood circulation promoting and blood stasis dispelling, the auxilliary simultaneously article that regulating the flow of QI to promote menstrual discharge is arranged, the present invention add on this basis used wind-damp dispelling medicine with the eliminating impediment of invigorating blood circulation, receive promising result.The Zaocys expelling wind and removing dampness can be removed cerebral vasospasm; Add the effect that strengthens wind-damp dispelling with Agkistrodon, make that rheumatism is removed, pain is ended; Assistant is with Scorpio, Rhizoma Gastrodiae spasmolytic endogenous wind stopping, detoxicating and resolving stagnation of pathogens, removing obstruction in the collateral to relieve pain, and ruton is then dizzy to be ended.It is dizzy for due to the liver-wind stirring up internally that the traditional Chinese medical science is thought, the endogenous wind stopping suppressing the hyperactive liver is the speciality of Scorpio, Rhizoma Gastrodiae, and can restrict the diffusing property of liter of eupolyphaga, Zaocys and Agkistrodon.Bright Olibanum, Myrrha (processed) are the instigator.More than all medicines, the property of medicine is pretty violent, solely goes into the effect that Liver Channel plays through sick institute, and the medicine of bright Olibanum, Myrrha (processed) had both been gone into Liver Channel to be multiplied by the pretty violent property of medicine, goes into heart channel, spleen channel again and the effect of a promoting blood circulation and stopping pain.Promoting tissue regeneration by removing blood stasis strengthens cerebrovascular, cardiovascular elasticity; Improve the ability of blood supply oxygen supply; Medicine of the present invention is in a word promptly adjusted the quality of blood; Again blood vessel is protected, made blood quality poor (congestion) vascular canal narrow (arteriosclerosis) obtain basic improvement, the various diseases that causes is therefrom thoroughly eliminated.
Often there are protopathy such as coronary heart disease, hypertension, diabetes in the cerebrovascular disease patient; It is inevitable to cause arteriosclerosis to become, and along with the progress of hypertension, hyperlipidemia and the hyperglycemia course of disease, causes cerebral arteries and branch's tube chamber thereof to narrow down; The elasticity variation, slow blood flow causes cerebral blood supply insufficiency in.The means of treatment cerebrovascular disease are limited at present, are mostly anticoagulant, and antiplatelet aggregation etc. can make shorten the course of treatment after the adding treatment by Chinese herbs, improve curative effect, obviously improve patient's symptom.
Adopt the beneficial effect that technique scheme produced to be: it is dizzy that Chinese medicine composition of the present invention can be used for treating the apoplexy sequela headache, and instant effect, toxic and side effects are little, and can prevention of stroke.The present invention is effective in cure to other cerebrovascular and dizziness, headache, waist, skelalgia etc., and the various symptoms that can alleviate arteriosclerosis, hyperlipidemia, coronary heart disease and caused by osteoporosis.
The specific embodiment
Embodiment 1
A kind of dizzy Chinese medicine composition of apoplexy sequela headache of treating, form by following Chinese medicine by weight:
Eupolyphaga 10 Zaocyss 15
Agkistrodon 15 Scorpios 10
Radix Notoginseng 15 bright Olibanums 20
Myrrha (processed) 20 whole days fiber crops 20
Bombyx Batryticatus 20 Radix Angelicae Sinensis 30.
Take by weighing medical material according to aforementioned proportion, wear into powder after drying, process capsule, every capsules contains 0.5g medical material powder.
Embodiment 2
A kind of dizzy Chinese medicine composition of apoplexy sequela headache of treating, form by following Chinese medicine by weight:
Eupolyphaga 5 Zaocyss 25
Agkistrodon 5 Scorpios 15
Radix Notoginseng 5 bright Olibanums 30
Myrrha (processed) 10 whole days fiber crops 30
Bombyx Batryticatus 10 Radix Angelicae Sinensis 45.
Take by weighing medical material according to aforementioned proportion, process honeyed pill.
Embodiment 3
A kind of dizzy Chinese medicine composition of apoplexy sequela headache of treating, form by following Chinese medicine by weight:
Eupolyphaga 15 Zaocyss 5
Agkistrodon 25 Scorpios 5
Radix Notoginseng 25 bright Olibanums 10
Myrrha (processed) 30 whole days fiber crops 10
Bombyx Batryticatus 30 Radix Angelicae Sinensis 15.
Take by weighing medical material according to aforementioned proportion, process the condensed water honeyed pill.
Embodiment 4
A kind of dizzy Chinese medicine composition of apoplexy sequela headache of treating, form by following Chinese medicine by weight:
Eupolyphaga 10 Zaocyss 15
Agkistrodon 15 Scorpios 10
Radix Notoginseng 15 bright Olibanums 20
Myrrha (processed) 20 whole days fiber crops 20
Bombyx Batryticatus 20 Radix Angelicae Sinensis 30.
Take by weighing medical material according to aforementioned proportion, every part of compositions adds 1 portion of Icing Sugar and 1 part of dextrin, processes granule.
Embodiment 5
A kind of dizzy Chinese medicine composition of apoplexy sequela headache of treating, form by following Chinese medicine by weight:
Eupolyphaga 9 Zaocyss 17
Agkistrodon 10 Scorpios 12
Radix Notoginseng 13 bright Olibanums 15
Myrrha (processed) 22 whole days fiber crops 21
Bombyx Batryticatus 25 Radix Angelicae Sinensis 35.
Take by weighing medical material according to aforementioned proportion, process tablet.
Embodiment 6
A kind of dizzy Chinese medicine composition of apoplexy sequela headache of treating, form by following Chinese medicine by weight:
Eupolyphaga 10 Zaocyss 15
Agkistrodon 15 Scorpios 10
Radix Notoginseng 15 bright Olibanums 20
Myrrha (processed) 20 whole days fiber crops 20
Bombyx Batryticatus 20 Radix Angelicae Sinensis 30.
Take by weighing medical material according to aforementioned proportion, process powder.
Embodiment 7
A kind of dizzy Chinese medicine composition of apoplexy sequela headache of treating, form by following Chinese medicine by weight:
Eupolyphaga 8 Zaocyss 13
Agkistrodon 21 Scorpios 7
Radix Notoginseng 17 bright Olibanums 11
Myrrha (processed) 14 whole days fiber crops 20
Bombyx Batryticatus 25 Radix Angelicae Sinensis 30.
Take by weighing medical material according to aforementioned proportion, process unguentum.
Embodiment 8
A kind of dizzy Chinese medicine composition of apoplexy sequela headache of treating, form by following Chinese medicine by weight:
Eupolyphaga 6 Zaocyss 7
Agkistrodon 24 Scorpios 13
Radix Notoginseng 24 bright Olibanums 12
Myrrha (processed) 13 whole days fiber crops 21
Bombyx Batryticatus 25 Radix Angelicae Sinensis 30.
Take by weighing medical material according to aforementioned proportion, process oral liquid.
The used Chinese crude drug of the application all adopts conventional method to concoct, the prepared slices of Chinese crude drugs of the used Chinese crude drug of the application embodiment for purchasing from pharmacy.
Adopting the headache of traditional Chinese medicine composition for treating apoplexy sequela of the present invention, dizzy 66 examples to obtain significant curative effect, as contrast, below is visual report with HUATUO ZAIZAO WAN treatment 66 examples:
One, clinical data
1, the standard of including in of case
(1) meets " new Chinese medicine clinical guidance principle " standard; (2) age is more than 45 years old; (3) dizzy with headache; (4) there are the change of atherosclerotic disease, optical fundus to have arteriosclerosis change or TCD (neck, cranium doppler ultrasound) to show VBI evidence (cerebral blood supply insufficiency); (5) cause of disease is clear and definite, like cervical spondylosis, coronary heart disease etc.
2, case exclusion standard
Get rid of aural vertigo and tumor, dizziness, headache that factors such as serious anemia cause.
3, collect patient's totally 132 examples meet above-mentioned standard in outpatient service,, be divided into two groups at random according to the prescription on individual diagnosis order.66 examples are organized in treatment, male 40 examples, and women 26 examples, the age is at 46-75 between year, the course of disease 7 days to 5 years.Accompanied with hypertension 24 examples wherein, diabetes 14 examples, coronary heart disease 12 examples, cervical spondylosis 16 examples.Matched group 66 examples, male 38 examples, women 28 examples, between age 45-76 year, the course of disease 9 days to 5 years, sick 26 examples of accompanied with hypertension wherein, diabetes 18 examples, coronary heart disease 12 examples, cervical spondylosis 12 examples.Two groups of patient's sexes, age, the course of disease, distribution and through the TCD check result through the equal not statistically significant of statistical procedures difference (P ﹥ 0.05), have comparability.
4, Therapeutic Method
All patients go into the group back and observe heart rate, blood pressure and one week of blood glucose, and former ill medicine is still by former therapeutic scheme medication.On blood pressure, glycemic control good basis, the treatment group adds each two of the embodiment of the invention 1 made capsule, and every day three times, taking medicine before meal was taken one month continuously.Matched group adds HUATUO ZAIZAO WAN (Qixing Pharmaceutical Co., Ltd., Guangzhou's production) and takes as directed, takes continuously 1 month.
5, observation of curative effect
5.1 efficacy assessment standard
With reference to " new Chinese medicine clinical research guideline " relevant criterion, mainly symptom and the TCD according to the patient changes judgement.Recovery from illness: dizzy companioned with headache primary symptom disappears, and TCD detects index and recovers normal; Produce effects: symptoms such as dizzy companioned with headache obviously alleviate, or dizzy slight, and headache disappears, and TCD detects index and makes moderate progress; Effectively: symptoms such as dizzy companioned with headache have some improvement; Invalid: doing well,improving is not obvious.
5.2 the comparison of two groups of curative effects
66 examples are organized in treatment, 30 examples of fully recovering, produce effects 18 examples, effective 12 examples, invalid 6 examples, total effective rate 90.91%.Matched group 66 examples, 24 examples of fully recovering, produce effects 16 examples, effective 14 examples, invalid 12 examples, total effective rate 81.82%.Two groups of total effective rates compare, and difference has statistical significance (P ﹤ 0.05).
5.3, the TCD testing result
After the treatment, two groups of VPVs all have raising (P ﹤ 0.05) in various degree before the treatment, and two groups of raising degree of comparing treatment group VPV are (P ﹤ 0.05) more obviously
5.4, safety index
The two groups of routine blood tests in treatment back, routine urinalysis, blood pressure, liver function, renal function, blood fat, blood glucose, electrocardiogram has no significant change, and shows that medicine of the present invention does not have obvious toxic-side effects to human body.
Claims (6)
1. treat the dizzy Chinese medicine composition of apoplexy sequela headache for one kind, it is characterized in that: form by following Chinese medicine by weight:
Eupolyphaga 5～15 Zaocyss 5～25
Agkistrodon 5～25 Scorpios 5～15
Radix Notoginseng 5～25 bright Olibanums 10～30
Myrrha (processed) 10～30 whole days fiber crops 10～30
Bombyx Batryticatus 10～30 Radix Angelicae Sinensis 15～45.
2. a kind of dizzy Chinese medicine composition of apoplexy sequela headache of treating as claimed in claim 1 is characterized in that: be made up of following Chinese medicine by weight:
Eupolyphaga 10 Zaocyss 15
Agkistrodon 15 Scorpios 10
Radix Notoginseng 15 bright Olibanums 20
Myrrha (processed) 20 whole days fiber crops 20
Bombyx Batryticatus 20 Radix Angelicae Sinensis 30.
3. treat the dizzy medicine of apoplexy sequela headache for one kind, it is characterized in that: process by claim 1 or 2 each described Chinese medicine compositions and pharmacy acceptable auxiliary.
4. a kind of dizzy medicine of apoplexy sequela headache of treating as claimed in claim 3, it is characterized in that: said medication preparation becomes peroral dosage form.
5. a kind of dizzy medicine of apoplexy sequela headache of treating as claimed in claim 4, it is characterized in that: said peroral dosage form is honeyed pill, condensed water honeyed pill, the watered pill, granule, capsule, tablet, powder, unguentum or oral liquid.
6. a kind of dizzy medicine of apoplexy sequela headache of treating as claimed in claim 5, it is characterized in that: said peroral dosage form is a capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210304469.5A CN102784310B (en) | 2012-08-24 | 2012-08-24 | Traditional Chinese medicine composition for treating headache and dizziness of apoplexy sequela |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210304469.5A CN102784310B (en) | 2012-08-24 | 2012-08-24 | Traditional Chinese medicine composition for treating headache and dizziness of apoplexy sequela |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102784310A true CN102784310A (en) | 2012-11-21 |
| CN102784310B CN102784310B (en) | 2014-09-10 |
Family
ID=47150027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210304469.5A Expired - Fee Related CN102784310B (en) | 2012-08-24 | 2012-08-24 | Traditional Chinese medicine composition for treating headache and dizziness of apoplexy sequela |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102784310B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1565599A (en) * | 2003-06-30 | 2005-01-19 | 李建中 | Chinese drug injection formulation for dissolving cerebral thrombus |
| CN101391073A (en) * | 2008-11-14 | 2009-03-25 | 杨文龙 | Da huoluo capsule preparation method |
| CN101721664A (en) * | 2008-11-04 | 2010-06-09 | 王生 | Traditional Chinese medicine for treating apoplectic hemiplegia and general paralysis |
-
2012
- 2012-08-24 CN CN201210304469.5A patent/CN102784310B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1565599A (en) * | 2003-06-30 | 2005-01-19 | 李建中 | Chinese drug injection formulation for dissolving cerebral thrombus |
| CN101721664A (en) * | 2008-11-04 | 2010-06-09 | 王生 | Traditional Chinese medicine for treating apoplectic hemiplegia and general paralysis |
| CN101391073A (en) * | 2008-11-14 | 2009-03-25 | 杨文龙 | Da huoluo capsule preparation method |
Non-Patent Citations (3)
| Title |
|---|
| 周志娴: "中医药治疗中风后遗症研究近况", 《云南中医学院学报》 * |
| 周永红: "中风后遗症证治近况", 《山东中医杂志》 * |
| 张娟等: "虫类药治疗中风病配伍应用", 《山东中医杂志》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102784310B (en) | 2014-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102614387B (en) | The Chinese medicine composition of prevention and therapy apoplexy and preparation method | |
| CN104013835A (en) | Traditional Chinese medicine for treating high blood pressure | |
| CN100586458C (en) | Medicine for treating cerebral apoplexy | |
| CN102357195B (en) | Medicinal composition for treating cardiovascular and cerebrovascular diseases, and preparation method and application thereof | |
| CN103417718B (en) | Pressure-reduction and fat-eliminating tea | |
| CN1907394B (en) | Medicine for treating diabetes foot | |
| CN103550688B (en) | A kind of Chinese medicine composition for the treatment of cardiopalmus | |
| CN101229345B (en) | Qi-replenishing and blood-enriching medicine | |
| CN101450189B (en) | Medicine for curing angiocardiopathy and cerebrovascular disease and its preparing method | |
| CN102784310B (en) | Traditional Chinese medicine composition for treating headache and dizziness of apoplexy sequela | |
| CN102940677B (en) | Medicine composition for treating diabetic foot | |
| CN102552724B (en) | Chinese medicine composite for curing hypertension | |
| CN101637577A (en) | Traditional Chinese medicine for curing hemorrhagic strokes | |
| CN111166849A (en) | Medicated bath composition for removing fatigue and improving sleep | |
| CN104739946A (en) | Health preserving microcapsule for preventing and treating hyperlipidemia, high blood pressure and high blood sugar | |
| CN1850160A (en) | Qidantongmai Tablet, and its preparing process | |
| CN110339323A (en) | A kind of Chinese medicine composition and its preparation method and application for treating bradycardia | |
| CN102406924B (en) | Medicine composition for treating cerebrovascular and cardiovascular diseases as well as preparation method and application thereof | |
| CN103070994B (en) | Plaster for treating cervical and lumbar spondylosis | |
| CN102836320B (en) | Chinese medicinal pill for treating tachyarrhythmia | |
| CN102319330A (en) | Traditional Chinese medicine cataplasma for treating hyperosteogeny and preparation method thereof | |
| CN105687799A (en) | Traditional Chinese medicine composition for treating epilepsy | |
| CN102940671A (en) | Medicine composition for treating diabetic foot | |
| CN103083403A (en) | Herbal composition for lowering likelihood of stroke and methods for healing stroke patients | |
| CN1279947C (en) | Traumatic injury treating medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: VOCATIONAL TECHNOLOGY TRAINING CT OF HEBEI ELECTRI Effective date: 20130118 Owner name: STATE ELECTRIC NET CROP. Free format text: FORMER OWNER: VOCATIONAL TECHNOLOGY TRAINING CT OF HEBEI ELECTRIC POWER CORP. Effective date: 20130118 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 050000 SHIJIAZHUANG, HEBEI PROVINCE TO: 100031 XICHENG, BEIJING |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20130118 Address after: 100031 Xicheng District West Chang'an Avenue, No. 86, Beijing Applicant after: State Grid Corporation of China Applicant after: Vocational & Technic Training Center of Hebei Electric Power Corporation Address before: 050000 Hebei city of Shijiazhuang province Donggang Road No. 56 Applicant before: Vocational & Technic Training Center of Hebei Electric Power Corporation |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140910 Termination date: 20200824 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |